- Home
- BP vs SNY Comparison
BP vs SNY Comparison
Compare BP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BP | SNY |
|---|---|---|
| Founded | 1889 | 1994 |
| Country | United Kingdom | France |
| Employees | 93700 | 74846 |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.3B | 101.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BP | SNY |
|---|---|---|
| Price | $44.40 | $44.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $44.43 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 7.4M | 2.6M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.18% | 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.52 | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | $11,332.35 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.83 | $42.33 |
| 52 Week High | $48.27 | $53.02 |
Technical Indicators
Market Signals| Indicator | BP | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 47.81 |
| Support Level | $43.58 | $43.32 |
| Resistance Level | $47.65 | $48.51 |
| Average True Range (ATR) | 0.78 | 0.59 |
| MACD | -0.06 | 0.21 |
| Stochastic Oscillator | 30.69 | 71.32 |
Price Performance
Historical ComparisonAbout BP BP p.l.c.
BP is an integrated energy company that explores for, produces, and refines oil and gas around the world. In 2025, it produced 1.2 million barrels of liquids and 6.5 billion cubic feet of natural gas per day. At the end of 2025, proved hydrocarbon reserves stood at 6.2 billion barrels of oil equivalent, 56% of which are liquids. The company operates refineries with a total crude distillation capacity of 1.56 million barrels of oil per day.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.